Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC
Recruiting · NCT06553885 · Registry updated 2026-04-01Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Ph II Study of Enfortumab Vedotin in Patients With Advanced or Metastatic CRC or HCC | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, epithelial neoplasm, hepatocellular carcinoma, intestinal disorder, liver disorder, neoplasm, rectal disorder | Recruiting | Phase 2 | 2026-04-01 | NCT06553885 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Astellas Pharma Inc | 43 |
| H. Lee Moffitt Cancer Center and Research Institute | 162 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Moffitt Cancer Center | Tampa | United States | 523 |